1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359–E386. PMID:
25220842.

2. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68:723–750. PMID:
29624699.

3. Pawlik TM, Poon RT, Abdalla EK, Zorzi D, Ikai I, Curley SA, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg. 2005; 140:450–457. PMID:
15897440.

4. Poon RT, Fan ST. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl. 2004; 10(2 Suppl 1):S39–S45.

5. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg. 1993; 218:145–151. PMID:
8393649.

6. Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg. 2003; 197:753–758. PMID:
14585409.

7. Cha CH, Ruo L, Fong Y, Jarnagin WR, Shia J, Blumgart LH, et al. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg. 2003; 238:315–321. PMID:
14501497.

8. Lu X, Zhao H, Yang H, Mao Y, Sang X, Miao R, et al. A prospective clinical study on early recurrence of hepatocellular carcinoma after hepatectomy. J Surg Oncol. 2009; 100:488–493. PMID:
19653238.

9. Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg. 2011; 253:453–469. PMID:
21263310.
10. Arnaoutakis DJ, Mavros MN, Shen F, Alexandrescu S, Firoozmand A, Popescu I, et al. Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis. Ann Surg Oncol. 2014; 21:147–154. PMID:
23959056.

11. Hirokawa F, Hayashi M, Asakuma M, Shimizu T, Inoue Y, Uchiyama K. Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinoma. Surg Oncol. 2016; 25:24–29. PMID:
26979637.

12. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000; 232:10–24. PMID:
10862190.

13. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: ascites and related complications. Clin Mol Hepatol. 2018; 24:230–277. PMID:
29991196.
14. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018; 69:182–236. PMID:
29628281.
15. Arima K, Nitta H, Beppu T, Nakagawa S, Okabe H, Imai K, et al. Impact of repeated hepatectomy on liver regeneration in hepatocellular carcinoma: a propensity score-based analysis. Anticancer Res. 2019; 39:965–970. PMID:
30711982.

16. Ochiai T, Inoue H, Watanabe N, Ito H, Toma A, Morimura R, et al. Outcome of a second hepatectomy in octogenarians with hepatocellular carcinoma recurrence: single centre's experience. ANZ J Surg. 2019; 89:1270–1274. PMID:
31280497.

17. Ho CM, Lee PH, Shau WY, Ho MC, Wu YM, Hu RH. Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities. Surgery. 2012; 151:700–709. PMID:
22284764.

18. Ferrer-Fàbrega J, Forner A, Liccioni A, Miquel R, Molina V, Navasa M, et al. Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Hepatology. 2016; 63:839–849. PMID:
26567038.
19. Zhang X, Li C, Wen T, Peng W, Yan L, Yang J. Treatment for intrahepatic recurrence after curative resection of hepatocellular carcinoma: salvage liver transplantation or re-resection/radiofrequency ablation? A Retrospective Cohort Study. Int J Surg. 2017; 46:178–185. PMID:
28890407.

20. Xia Y, Li J, Liu G, Wang K, Qian G, Lu Z, et al. Long-term effects of repeat hepatectomy vs percut aneous radiof requency ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial. JAMA Oncol. 2020; 6:255–263. PMID:
31774468.
21. Feng Y, Wu H, Huang DQ, Xu C, Zheng H, Maeda M, et al. Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤ 5 cm) after initial curative resection. Eur Radiol. 2020; 30:6357–6368. PMID:
32529568.

22. Lu LH, Mei J, Kan A, Ling YH, Li SH, Wei W, et al. Treatment optimization for recurrent hepatocellular carcinoma: repeat hepatic resection versus radiofrequency ablation. Cancer Med. 2020; 9:2997–3005. PMID:
32108433.

23. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg. 1999; 229:216–222. PMID:
10024103.
24. Shimada M, Takenaka K, Gion T, Fujiwara Y, Kajiyama K, Maeda T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology. 1996; 111:720–726. PMID:
8780578.

25. Shah SA, Greig PD, Gallinger S, Cattral MS, Dixon E, Kim RD, et al. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg. 2006; 202:275–283. PMID:
16427553.

26. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016; 150:835–853. PMID:
26795574.

27. Shimoda M, Tago K, Shiraki T, Mori S, Kato M, Aoki T, et al. Risk factors for early recurrence of single lesion hepatocellular carcinoma after curative resection. World J Surg. 2016; 40:2466–2471. PMID:
27138886.

28. Wang Y, Chen Y, Ge N, Zhang L, Xie X, Zhang J, et al. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization. Ann Surg Oncol. 2012; 19:3540–3546. PMID:
22532305.

29. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003; 124:91–96. PMID:
12512033.
